Back to Search
Start Over
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
- Source :
- The Lancet; August 2023, Vol. 402 Issue: 10402 p613-626, 14p
- Publication Year :
- 2023
-
Abstract
- Weight reduction is essential for improving health outcomes in people with obesity and type 2 diabetes. We assessed the efficacy and safety of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, versus placebo, for weight management in people living with obesity and type 2 diabetes.
Details
- Language :
- English
- ISSN :
- 01406736 and 1474547X
- Volume :
- 402
- Issue :
- 10402
- Database :
- Supplemental Index
- Journal :
- The Lancet
- Publication Type :
- Periodical
- Accession number :
- ejs63408880
- Full Text :
- https://doi.org/10.1016/S0140-6736(23)01200-X